Roberts, M. S., Anstine, L. J., Finke, V. S., Bryson, B. L., Webb, B. M., Weber-Bonk, K. L., . . . Keri, R. A. (2020). KLF4 defines the efficacy of the epidermal growth factor receptor inhibitor, erlotinib, in triple-negative breast cancer cells by repressing the EGFR gene. Breast Cancer Res.
Chicago Stili AlıntıRoberts, Melyssa S., Lindsey J. Anstine, Viviane S. Finke, Benjamin L. Bryson, Bryan M. Webb, Kristen L. Weber-Bonk, Darcie D. Seachrist, Parth R. Majmudar, ve Ruth A. Keri. "KLF4 Defines the Efficacy of the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, in Triple-negative Breast Cancer Cells By Repressing the EGFR Gene." Breast Cancer Res 2020.
MLA AlıntıRoberts, Melyssa S., et al. "KLF4 Defines the Efficacy of the Epidermal Growth Factor Receptor Inhibitor, Erlotinib, in Triple-negative Breast Cancer Cells By Repressing the EGFR Gene." Breast Cancer Res 2020.